Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
| ▸ | BCHE | P06276 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24764429 | 0.85 | HRH3 (0.35) | NPC1ALDH1A1TSHRKDM1ABCHE | |
| SCHEMBL19655526 | 0.84 | TSHR (0.32) | ALDH1A1TSHR | |
| SCHEMBL24673651 | 0.84 | HRH3 (0.40) | NPC1ALDH1A1TSHRKDM1ABCHE | |
| SCHEMBL23806645 | 0.82 | NPC1 (0.33) | NPC1 | |
| SCHEMBL24672510 | 0.78 | NPC1 (0.34) | NPC1 | |
| SCHEMBL25502491 | 0.75 | HRH3 (0.36) | NPC1KDM1A | |
| SCHEMBL27888474 | 0.72 | NPC1 (0.31) | NPC1 | |
| SCHEMBL23806713 | 0.72 | TSHR (0.32) | NPC1TSHR | |
| SCHEMBL25701241 | 0.71 | HRH3 (0.40) | NPC1ALDH1A1TSHR | |
| SCHEMBL20148029 | 0.70 | NPC1 (0.37) | NPC1KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219945-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219945-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | NPC1 3159/4885ALDH1A1 2776/4885TSHR 3319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.